Note 12 - Segment Information (Tables)

12 Months Ended

Jun. 30, 2020

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended June 30,
	2020			2019			2018
Net sales:
Protein Sciences	$	555,352		$	543,159		$	482,378
Diagnostics and Genomics		184,549			171,674			161,151
Intersegment		(1,210	)		(827	)		(536	)
Consolidated net sales	$	738,691		$	714,006		$	642,993
Operating Income:
Protein Sciences	$	234,929		$	240,919		$	209,880
Diagnostics and Genomics		14,965			10,079			35,496
Segment operating income		249,894			250,998			245,376
Costs recognized upon sale of acquired inventory		-			(3,739	)		(2,455	)
Amortization of acquired intangible assets		(60,865	)		(58,550	)		(46,983	)
Gain on escrow settlement		7,169			-			-
Acquisition related expenses		(416	)		(2,282	)		(24,429	)
Restructuring costs		(87	)		-			(376	)
Stock-based compensation		(34,262	)		(33,057	)		(28,240	)
Corporate general, selling and administrative expenses		(4,015	)		(6,651	)		(6,715	)
Consolidated operating income	$	157,419		$	146,719		$	136,178

	Year Ended June 30,
	2020		2019		2018
Consumables revenue - Protein Sciences	$	431,052	$	430,655	$	384,350
Consumables revenue - Diagnostics and Genomics		171,590		158,324		150,388
Total consumable revenue	$	602,642	$	588,979	$	534,738

	Year ended June 30,
Long-lived assets:	2020		2019
United States and Canada	$	162,039	$	138,016
Europe		13,120		14,439
Asia		1,670		1,584
Total long-lived assets	$	176,829	$	154,039
Intangible assets:
United States and Canada	$	499,875	$	556,951
Europe		12,349		16,637
Asia		4,321		5,841
Total intangible assets	$	516,545	$	579,429